Suzhou-based Convergen has secured $15 million in Seed+ financing to advance its next-generation targeted protein degradation platform and pipeline for neurodegenerative diseases, as the Chinese biotech seeks to translate its TRIM21-based approach for selectively eliminating pathological protein aggregates into clinical-stage therapies.
SUZHOU, China, August 31, 2026 — Chinese biotechnology company Convergen (沃生医药) has completed a $15 million Seed+ financing round to accelerate development of its proprietary targeted protein degradation technology and advance its pipeline targeting neurodegenerative and other diseases driven by pathological protein aggregation. (prnewswire.com)
The round was led by MPCi (Matrix Partners China/经纬创投), with participation from LAV (Lilly Asia Ventures), BioTrack Capital (博远资本) and another leading biotech-focused investment fund.
The new financing follows a $10 million Seed round announced in December 2025, which was led exclusively by Qiming Venture Partners. Together, the two announced rounds have provided Convergen with approximately $25 million in financing within nine months as it moves its lead program toward the clinic. (prnewswire.com)
According to Convergen, proceeds from the latest financing will be used to further develop its proprietary protein degrader platform and accelerate its pipeline for neurodegenerative disorders and other protein-aggregation diseases.
CEO and co-founder Dr. Jinquan Sun (孙巾荃) said the company has made significant progress validating its protein degradation platform and advancing its core pipeline. The new capital is expected to help move its lead asset toward clinical development while supporting additional pipeline programs. (prnewswire.com)
Targeting a Fundamental Driver of Neurodegenerative Disease
Convergen is developing a new generation of targeted protein degradation (TPD) medicines designed to eliminate pathological protein aggregates.
Protein aggregation is a defining feature of several major neurodegenerative diseases. Alzheimer’s disease, for example, is characterized by pathological accumulation of proteins including amyloid-beta and tau, while Parkinson’s disease is associated with abnormal aggregation of alpha-synuclein.
The challenge is that conventional therapeutic strategies frequently attempt to inhibit production, aggregation or activity of disease-associated proteins rather than selectively removing already-formed pathological assemblies.
Convergen is taking a different approach.
Its technology is designed to harness the cell’s natural protein-disposal machinery to selectively eliminate aggregated or multimeric forms of disease-associated proteins while potentially sparing their normal monomeric counterparts.
That distinction could be particularly important in CNS diseases where the normal form of a protein may retain important biological functions.
TrimTAC: A Different Approach to Targeted Protein Degradation
At the center of Convergen’s technology is TrimTAC, a targeted protein degradation platform built around the E3 ubiquitin ligase TRIM21.
Traditional PROTACs are bifunctional molecules that bring a disease-associated protein into proximity with an E3 ubiquitin ligase, marking the target for destruction by the proteasome.
However, much of the first generation of targeted protein degradation has relied on a relatively small number of E3 ligases, particularly CRBN and VHL.
Convergen’s scientific foundation introduces TRIM21 as an alternative degradation mechanism with a particularly interesting property: its activity can depend on the multimeric state of the target protein.
This potentially allows TRIM21-based degraders to distinguish between abnormal aggregated proteins and their normal soluble forms.
The scientific basis for the technology was established by work from Convergen scientific co-founder Prof. Ting Han (韩霆) and collaborators at the National Institute of Biological Sciences, Beijing and Tsinghua University’s Tsinghua Institute of Multidisciplinary Biomedical Research.
In November 2024, the researchers published a study in Cell titled “Selective degradation of multimeric proteins by TRIM21-based molecular glue and PROTAC degraders.” Read the Cell study
The researchers identified a small molecule capable of acting as a TRIM21-dependent molecular glue and subsequently used structural insights to construct TRIM21-based bifunctional degraders called TrimTACs. (doi.org)
Why TRIM21 Could Matter
The biological behavior of TRIM21 gives the approach an unusual degree of potential selectivity.
When recruited to multimeric substrates, neighboring TRIM21 molecules can bring their RING domains together, activating the ubiquitination machinery required for degradation.
Researchers demonstrated that TrimTAC molecules could preferentially degrade proteins assembled within biomolecular condensates, while leaving corresponding proteins in their non-aggregated state largely unaffected. (doi.org)
Conceptually, the process can be summarized as:
Pathological protein aggregate → TrimTAC recruitment → TRIM21 activation → ubiquitination → proteasomal degradation
The original Cell study demonstrated proof-of-concept degradation of multimeric protein assemblies and suggested that the technology could eventually be applied to pathological aggregates associated with neurodegenerative disease, as well as abnormal protein assemblies involved in autoimmune disease and cancer. (doi.org)
For Convergen, that creates an opportunity to build a therapeutic platform around state-selective protein degradation rather than simply target-selective degradation.
Potential Application in Alzheimer’s and Other CNS Diseases
The initial commercial focus is particularly relevant to neurodegenerative disease.
Many of these disorders involve proteins that exist in both normal and pathological states. Completely eliminating a protein can therefore create safety or biological-function concerns.
A degrader capable of preferentially recognizing a pathological multimeric or aggregated state could theoretically provide a wider therapeutic window.
| Disease area | Major pathological protein aggregates | Potential rationale for selective degradation |
|---|---|---|
| Alzheimer’s disease | Amyloid-beta, tau | Remove pathological aggregates while minimizing disruption of normal protein biology |
| Parkinson’s disease | Alpha-synuclein | Target toxic oligomeric/aggregated forms |
| ALS / FTD | TDP-43 and other proteins | Eliminate disease-associated protein assemblies |
| Huntington’s disease | Mutant huntingtin aggregates | Reduce accumulation of pathological protein assemblies |
These disease-specific applications remain investigational for Convergen, and the company has not publicly disclosed detailed clinical-stage candidates against each of these targets.
The key question will therefore be whether the selectivity demonstrated in laboratory models can be translated into drug candidates with suitable brain exposure, pharmacokinetics, safety and degradation activity in humans.
From Academic Discovery to Drug Development
Convergen’s strategy is closely tied to the academic work of scientific founder Prof. Ting Han, an investigator at the National Institute of Biological Sciences, Beijing.
Han has worked extensively in targeted protein degradation, including earlier research explaining how anticancer sulfonamides induce degradation of RBM39 through recruitment to DCAF15, published in Science in 2017. (nature.com)
His laboratory’s subsequent TRIM21 research established another potential route into targeted protein degradation.
The 2024 Cell study identified TRIM21-dependent molecular-glue activity and demonstrated that TRIM21-based PROTACs could selectively degrade proteins present in multimeric assemblies.
The researchers concluded that the approach could potentially be extended to disease-associated assemblies including amyloid-like aggregates implicated in neurodegeneration, oncogenic biomolecular condensates and higher-order immune signaling complexes. (doi.org)
Convergen was established to translate this emerging biology into therapeutic candidates.
$25 Million Raised Across Two Rounds
The latest financing also represents a rapid follow-on to Convergen’s previous capital raise.
In December 2025, the company announced a $10 million Seed financing led by Qiming Venture Partners.
That funding was earmarked for development of the TrimTAC platform and advancement of an early-stage pipeline targeting neurodegenerative diseases and other conditions with significant unmet medical needs. (prnewswire.com)
The latest $15 million Seed+ round brings Convergen’s publicly announced financing from those two rounds to approximately $25 million.
| Financing | Date | Amount | Investors |
|---|---|---|---|
| Seed | December 2025 | $10M | Qiming Venture Partners |
| Seed+ | August 2026 | $15M | MPCi/Matrix Partners China (lead), LAV, BioTrack Capital and another biotech fund |
| Total announced | — | $25M | — |
The participation of both specialist healthcare investors and major venture firms provides Convergen with additional financial backing as it attempts to move from platform validation toward clinical development. (prnewswire.com)
Moving the Lead Asset Toward the Clinic
Convergen has not yet publicly disclosed extensive details about its lead CNS candidate, including its specific molecular target, development code or expected first-in-human indication.
The company did, however, state that the new financing will allow it to accelerate its lead asset toward the clinic while continuing development of additional pipeline programs. (prnewswire.com)
That makes the next stage of Convergen’s development particularly important.
The 2024 academic research established a compelling biological concept, but the requirements for a practical CNS medicine are considerably higher.
A successful candidate will need not only to recruit TRIM21 and selectively degrade pathological aggregates but also achieve adequate exposure in the central nervous system, cross the blood-brain barrier where necessary, demonstrate durable pharmacological activity and maintain an acceptable safety profile.
The transition from TrimTAC proof-of-concept to a clinical drug candidate will therefore represent a critical validation point for the company.
A New Frontier for Protein Degradation
Targeted protein degradation has emerged as one of the biotechnology industry’s most active drug-development areas, but much of the field has historically focused on degrading individual soluble proteins.
Convergen is pursuing a different opportunity: degrading pathological protein states.
That distinction could be particularly valuable in neurodegeneration, where abnormal protein folding, oligomerization and aggregation are fundamental features of disease biology.
Rather than merely asking which protein should be removed, Convergen’s technology attempts to address another question:
Which form of that protein should be removed?
If TrimTAC can reliably distinguish pathogenic aggregates from physiologically important monomeric proteins, the platform could potentially open a new branch of targeted protein degradation focused on Alzheimer’s disease, Parkinson’s disease and other disorders that have historically proved exceptionally difficult for small-molecule drug development.
The new $15 million financing gives Convergen additional resources to test that proposition.
The key milestones to watch will now be disclosure of its lead CNS candidate and target, selection of a clinical development candidate, IND-enabling studies and eventual entry into first-in-human trials.
For a company still at the preclinical stage, those milestones will determine whether the intriguing biology behind TRIM21 and TrimTAC can ultimately be transformed into a new class of medicines for neurodegenerative disease.
References
- Convergen — $15 Million Seed+ Financing Announcement via PR Newswire
- PR Newswire Asia — Convergen Secures $15 Million Seed+ Financing
- Investment界 — 沃生医药完成1500万美元Seed+融资
- Convergen — $10 Million Seed Financing Announcement
- Cell — Selective Degradation of Multimeric Proteins by TRIM21-Based Molecular Glue and PROTAC Degraders
- Tsinghua University — Han and Huang Laboratories Develop Selective Multimeric Protein Degradation Technology
- Nature Communications — Elaboration of Molecular Glues That Target TRIM21 into TRIMTACs That Degrade Protein Aggregates
